Successfully navigating first launches has become bigger, more expensive, and more complex than ever before for emerging pharma companies. In this webinar, ZS Principal Ben Hohn and other industry experts break down the basic strategies of first launches, how companies can prepare for them, and how first launches in rare diseases and oncology have performed over the past decade. Later, Ben and the other panelists discuss their experiences in commercialization. This session was part of the 2021 LSX World Congress, held February 1-5.


Presenter and moderator: Ben Hohn, Principal - Launch, BD, Pipeline and Product Development Strategy, ZS


Panel: Liz Barrett, CEO, Urogen; Naseem Amin, CEO, gmp-orphan; Kieran Rooney, VP, Strategic Alliances and Licensing, Amryt Pharma